Antipsychotic medicines differ in formulation, effects and monitoring
Antipsychotics can reduce psychotic symptoms and relapse risk, but they are not interchangeable “strong” and “weak” versions of one treatment. Oral tablets, dissolving tablets, liquids and long-acting injections solve different practical problems. Each medicine has a distinct balance of metabolic, movement, hormonal, sedating and cardiovascular effects, so selection is a shared clinical decision and monitoring is part of treatment, not an optional extra.
Key takeaways
- The active ingredient matters more than the delivery format: a long-acting injection changes exposure and appointment planning but does not erase that medicine’s adverse-effect profile.
- Weight, waist, blood pressure, glucose, lipids, movement symptoms and sometimes prolactin or ECG findings should be considered before and during treatment.
- Restlessness, stiffness, sedation or slowed activity can overlap with illness symptoms, making a specific side-effect timeline more useful than stopping treatment abruptly.
What can antipsychotic medicine do, and what can it not do alone?
Antipsychotics are used for symptoms such as hallucinations, delusions, severe thought disorganisation and agitation in schizophrenia and other conditions. They may also be used in bipolar disorder, severe depression or other specialist contexts. The indication matters because the expected benefit, duration and alternatives differ.
Medicine is only one part of schizophrenia care. Psychological treatment, family intervention, physical healthcare, social and occupational support and early-intervention services address needs that a tablet cannot. NICE advises that a first presentation of sustained psychotic symptoms should not be started on antipsychotic treatment in primary care without consultant-psychiatrist involvement; see its psychosis and schizophrenia recommendations.
How do oral and long-acting formulations differ?
| Formulation | What it may change | What it does not tell you |
|---|---|---|
| Standard oral tablet or liquid | Daily routine, flexible adjustment and ability to identify recent missed doses | Whether the medicine is effective or tolerable for this person |
| Orodispersible tablet | Swallowing convenience and how the dose is taken | Faster or stronger antipsychotic action |
| Modified-release tablet | Release timing and whether the tablet must remain whole | Interchangeability with immediate-release strengths or schedules |
| Long-acting injection (LAI/depot) | Dosing interval, clinic attendance and more sustained exposure after each injection | Freedom from metabolic, movement, prolactin or cardiac effects |
NICE recommends considering an LAI after an acute episode when the person prefers it or when avoiding unintentional or covert non-adherence is a clinical priority. Preference, injection-site experience, travel, clinic access, the method for establishing tolerability and what happens if adverse effects occur all matter. An injection cannot be removed after administration, so the plan needs to be clear before the first dose.
The exact formulation name also matters. For example, standard and extended-release quetiapine have different handling instructions. A milligram-to-milligram swap between release forms or between oral and injectable products should never be inferred from a catalogue.
Why do side-effect discussions differ between medicines?
All antipsychotics can cause adverse effects, but their relative patterns differ. Olanzapine commonly raises questions about appetite, weight, glucose and lipids. Risperidone may raise prolactin and can cause movement effects. Aripiprazole can be less sedating for some people but may cause marked inner restlessness or impulse-control problems. Quetiapine can cause drowsiness, postural dizziness, appetite and metabolic effects.
Those summaries do not rank the medicines and do not predict an individual response. Other factors include previous benefit, heart rhythm, seizures, diabetes, blood pressure, prolactin-related symptoms, constipation, falls, pregnancy, smoking, alcohol or substance use and interacting medicines. HealthHub’s current guides for olanzapine, quetiapine and aripiprazole illustrate why each ingredient needs its own discussion.
What does monitoring look for?
Before treatment, recognised guidance recommends recording weight, waist circumference, pulse, blood pressure, glucose or HbA1c, lipids, prolactin, movement symptoms, nutrition and activity. An ECG may be indicated by the product information, heart risk or inpatient setting. Follow-up tracks benefit and functioning alongside adverse effects, because a technically normal result does not make disabling restlessness or sedation acceptable.
| Domain | Examples to record or test | Why it matters |
|---|---|---|
| Metabolic | Weight, waist, blood pressure, glucose/HbA1c, lipids | Detects medicine-associated weight and cardiometabolic change |
| Movement | Tremor, stiffness, spasms, restlessness, slowed movement, involuntary face or limb movements | Distinguishes treatable adverse effects from anxiety, agitation or illness symptoms |
| Hormonal/sexual | Menstrual change, breast symptoms, sexual function; prolactin when relevant | Identifies clinically important prolactin effects |
| Cardiovascular | Pulse, blood pressure, fainting history and ECG when indicated | Checks postural and rhythm concerns |
| Everyday function | Alertness, sleep, swallowing, constipation, driving, work and adherence | Measures whether the formulation is sustainable |
Monitoring should become more frequent when treatment changes or results are abnormal. It should not be postponed until the annual review when rapid weight gain, new movement symptoms or significant functional impairment appears.
Which symptoms need urgent assessment?
High fever with severe stiffness, confusion, altered consciousness or unstable pulse or blood pressure can indicate neuroleptic malignant syndrome and needs emergency assessment. New severe muscle spasm affecting the neck, jaw, eyes, breathing or swallowing also needs urgent care. Seek prompt help for fainting, seizure, chest pain, severe allergic swelling, suspected overdose or new suicidal or violent crisis.
New or worsening hallucinations, suspiciousness, disorganisation, major sleep change, withdrawal from usual activity or missed treatment may be early relapse signs for some people. The useful response is the person’s agreed relapse or crisis plan, not an unsupervised extra dose or sudden medicine change.
What changes the answer?
- Diagnosis and current phase. First-episode psychosis, maintenance treatment, bipolar mania and augmentation for depression are different decisions.
- Previous response. Benefit and adverse effects from a known medicine often matter more than a general class comparison.
- Formulation preference. Daily tablets, swallowing, privacy, travel and clinic attendance affect what is workable.
- Physical health. Diabetes, obesity, cardiovascular disease, seizures, constipation, falls and movement disorders change risk.
- Other substances and medicines. Alcohol, smoking changes, sedatives, stimulants, recreational drugs and interacting prescriptions can alter exposure or symptoms.
- Pregnancy or pregnancy planning. Risks differ by medicine and stage, and abrupt stopping can also carry substantial risk.
What should you bring to a medicine review?
Bring the exact packs or injection record, current dose schedule, missed doses, smoking or alcohol changes, every prescribed and non-prescribed product, and the dates of new sleep, appetite, movement, menstrual, sexual or alertness changes. Ask which effects the medicine is targeting, how success will be measured, which laboratory checks are due and who is responsible for each follow-up.
In Singapore, call 995 for immediate danger. National mindline 1771 and Samaritans of Singapore 1767 provide 24-hour support. The schizophrenia condition page and mental-health category can help identify catalogue terms but cannot select or stop treatment.
Sources
- NICE: Psychosis and schizophrenia in adults—recommendations.
- HealthHub Singapore: Olanzapine.
- HealthHub Singapore: Quetiapine.
- HealthHub Singapore: Aripiprazole.
- HealthHub MindSG: Preventing self-harm and suicide—helplines.
